Synthetic Biologics Reports Second Quarter 2017 Operational Highlights And Financial Results
ROCKVILLE, Md., Aug. 3, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the three months ended June 30, 2017.
"During the second quarter, we achieved additional and exciting progress for our lead microbiome-focused programs," said Jeff Riley, President and Chief Executive Officer of Synthetic Biologics. "The important momentum generated during the quarter is perhaps best illustrated by the FDA's granting of a Breakthrough Therapy Designation to ribaxamase, the first ever such designation of a drug candidate for the prevention of Clostridium difficile infection (CDI). We have submitted a request for a Type-B multidisciplinary meeting with the FDA to discuss potential options to expedite the development and review timelines for ribaxamase's clinical advancement and path towards marketing approval.
"During the second quarter, we achieved additional and exciting progress for our lead microbiome-focused programs," said Jeff Riley, President and Chief Executive Officer of Synthetic Biologics. "The important momentum generated during the quarter is perhaps best illustrated by the FDA's granting of a Breakthrough Therapy Designation to ribaxamase, the first ever such designation of a drug candidate for the prevention of Clostridium difficile infection (CDI). We have submitted a request for a Type-B multidisciplinary meeting with the FDA to discuss potential options to expedite the development and review timelines for ribaxamase's clinical advancement and path towards marketing approval.